High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa

Published: 27 September 2019| Version 1 | DOI: 10.17632/9mhhh2zjbb.1
Contributors:
Mondana Ghias,
Andrew Johnston,
Allison Kutner,
Robert Micheletti,
Steven Cohen,
Dean Hosgood

Description

JAAD-D-19-01225 High-dose, high-frequency infliximab: A novel treatment paradigm for hidradenitis suppurativa. Appendix Figure 1.

Files

Categories

Dermatology, Medical Dermatology, Prospective Cohort Study, Hidradenitis Suppurativa

License